9.50
0.85%
0.08
アフターアワーズ:
9.52
0.02
+0.21%
前日終値:
$9.42
開ける:
$9.48
24時間の取引高:
3.27M
Relative Volume:
1.17
時価総額:
$967.56M
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-1.7336
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
-6.86%
1か月 パフォーマンス:
-27.65%
6か月 パフォーマンス:
-65.28%
1年 パフォーマンス:
-63.09%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
NTLA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.50 | 967.56M | 45.97M | -508.80M | -382.65M | -5.48 |
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-04-13 | 開始されました | Canaccord Genuity | Buy |
2023-03-21 | 開始されました | Bernstein | Outperform |
2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2022-09-21 | 開始されました | JP Morgan | Overweight |
2022-09-01 | 開始されました | Citigroup | Sell |
2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
2022-06-16 | 開始されました | BofA Securities | Buy |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-02-18 | 開始されました | William Blair | Outperform |
2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
2022-01-31 | 開始されました | Cowen | Outperform |
2022-01-07 | 開始されました | Piper Sandler | Overweight |
2021-10-05 | 開始されました | Guggenheim | Buy |
2021-09-24 | 開始されました | Stifel | Buy |
2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
2021-06-11 | 開始されました | H.C. Wainwright | Buy |
2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-27 | 開始されました | Truist | Buy |
2020-10-14 | 開始されました | Wells Fargo | Overweight |
2020-09-18 | 開始されました | Goldman | Buy |
2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
2019-07-09 | 開始されました | Robert W. Baird | Outperform |
2019-06-10 | 開始されました | ROTH Capital | Neutral |
2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
2018-10-29 | 開始されました | Credit Suisse | Neutral |
2018-09-21 | 開始されました | Raymond James | Mkt Perform |
2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
2017-11-01 | 繰り返されました | Jefferies | Buy |
2017-06-22 | 再開されました | Jefferies | Buy |
2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
2025-01-20 | Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Avanza Fonder AB Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc. - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Intellia Loses 21.6% in a Week: How Should You Play the Stock? - MSN
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
2025-01-17 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
(NTLA) Technical Pivots with Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation - Markets Insider
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
Intellia to submit gene-editing therapy NTLA-2002 to FDA in 2026 - Angioedema News Today
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out - Markets Insider
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out - Markets Insider
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade) - Seeking Alpha
2025-01-14 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $12.00 by Analysts at The Goldman Sachs Group - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect - AccessWire
Intellia Therapeutics - The Pharma Letter
Intellia Therapeutics: Buying The Path To Commercialization (NASDAQ:NTLA) - Seeking Alpha
13 Analysts Have This To Say About Intellia Therapeutics - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $40.00 at Oppenheimer - MarketBeat
Intellia stock target cut at Oppenheimer on program discontinuations - Investing.com
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Intellia Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital - Yahoo Finance
Insider Sellers Might Regret Selling Intellia Therapeutics Shares at a Lower Price Than Current Market Value - Simply Wall St
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo - Yahoo Finance
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA) - MarketBeat
Peering Into Intellia Therapeutics's Recent Short Interest - Benzinga
Gene editing stocks drop as Intellia announces layoffs - MSN
Why Is Intellia Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Intellia stock hits 52-week low at $11.34 amid market challenges By Investing.com - Investing.com South Africa
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat
Intellia cuts 27% of workforce as it eyes commercial launch - The Business Journals
Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at BMO Capital Markets - MarketBeat
Intellia stock hits 52-week low at $11.34 amid market challenges - Investing.com
Wells Fargo & Company Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia to stop work on rare disease therapy, lay off staff - BioPharma Dive
CRISPR gene editing company cuts program and jobs - The Pharma Letter
Intellia Therapeutics Restructures to Focus on Late-Stage Programs - TipRanks
Intellia Therapeutics stock falls following strategic reorganization - Investing.com
Intellia Therapeutics stock falls following strategic reorganization By Investing.com - Investing.com Australia
CRISPR biotech Intellia cuts staff as it eyes 2027 launch - pharmaphorum
Intellia to cut 27% of workforce, discontinue NTLA-3001 - MSN
Intellia to cut 27% of workforce, discontinue NTLA-3001 (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
Intellia Therapeutics Inc (NTLA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
Hicks Derek | EVP, Chief Business Officer |
Jan 03 '25 |
Sale |
12.18 |
6,502 |
79,194 |
59,878 |
LEONARD JOHN M | President and CEO |
Jan 03 '25 |
Sale |
12.18 |
26,807 |
326,509 |
941,115 |
Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '25 |
Sale |
12.18 |
8,966 |
109,206 |
77,388 |
Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '25 |
Sale |
12.18 |
7,422 |
90,400 |
64,048 |
Clark Eliana | EVP, Chief Technical Officer |
Jan 02 '25 |
Sale |
12.03 |
556 |
6,689 |
71,470 |
Dube Michael P | VP, Chief Accounting Officer |
Oct 02 '24 |
Sale |
19.01 |
2,012 |
38,248 |
47,012 |
Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '24 |
Sale |
22.93 |
405 |
9,287 |
71,470 |
Verwiel Frank | Director |
Jun 17 '24 |
Sale |
25.00 |
1,505 |
37,625 |
17,948 |
大文字化:
|
ボリューム (24 時間):